KR950703962A - 중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System) - Google Patents

중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System)

Info

Publication number
KR950703962A
KR950703962A KR1019950702355A KR19950702355A KR950703962A KR 950703962 A KR950703962 A KR 950703962A KR 1019950702355 A KR1019950702355 A KR 1019950702355A KR 19950702355 A KR19950702355 A KR 19950702355A KR 950703962 A KR950703962 A KR 950703962A
Authority
KR
South Korea
Prior art keywords
alkyl
treatment
formula
compound
group
Prior art date
Application number
KR1019950702355A
Other languages
English (en)
Inventor
라이너 슐렉커
한스-외르크 트라이버
베르톨트 벨
한스 페터 호프만
Original Assignee
방게르트, 비베르바흐
바스프 악티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 방게르트, 비베르바흐, 바스프 악티엔게젤샤프트 filed Critical 방게르트, 비베르바흐
Publication of KR950703962A publication Critical patent/KR950703962A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

중추 신경 장해를 조절하기 위한 약물 제조를 위한 트리아졸로퀴나졸린의 용도를 기재하고 있다. 트리아졸로퀴나졸린은 하기 식(Ⅰ)과 같다.
상기 식에서 R1, R2및 X는 설명에 정의된 바와 같다.

Description

중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (3)

  1. 식(Ⅰ)의 화합물 및 생리학적으로 용인되는 산부가염의 중추 신경 장해 치료 약물의 제조를 위한 용도.
    상기식에서, X는 카르복실(이는 생리학적으로 용인되는 아민 양이온 또는 금속 양이온과의 염의 형태로 적합하다).[여기서, R4은 C1-8알킬, 고리에 3내지 8개의 탄소 원자를 갖는 시클로알킬, 벤진, (CH2)n-O-R5또는중의 하나인 기(여기서, n은 2, 3 또는 4이고, R5및 R6은 각각 C1-3-알킬이다)]. 히드록시-C1-4-알킬, 니트릴-C1-4-알킬, 테트라졸일, 카르보닐아미노테트라졸 또는 카르바모일이고, R1은 R2와 같거나 다르며, 수소, 불소, 염소 또는 브롬 원자, 트리플루오로메틸, 니트로, 아미노, C1-5-알킬, 모노 또는 디-C1-5-알킬아미노기, C1-6-알콕시기, C1-6-알킬티오,C1-6-알킬슐페닐, -C1-6알킬술포닐, 디-C1-6-알킬아미노술포닐기, 또는 R1및 R2는 함께 메틸렌-또는 에틸렌디옥시기 또는 C3-5-알킬렌기를 형성한다.
  2. 제1항에 따른 식(Ⅰ)의 화합물의 내용물을 가지는 중추 신경 장해의 치료를 위한 약물.
  3. 제1항에 따른 식(Ⅰ)의 화합물을 치료 유효량 투여하는 것으로 이루어지는, 중추신경 장애 환자의 치료방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019950702355A 1992-12-10 1993-12-06 중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System) KR950703962A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DEP4241564.0 1992-12-10
DE4241564A DE4241564A1 (de) 1992-12-10 1992-12-10 Triazolochinazoline zur Behandlung zentralnervöser Erkrankungen
PCT/EP1993/003424 WO1994013294A1 (de) 1992-12-10 1993-12-06 Triazolochinazoline zur behandlung zentralnervöser erkrankungen

Publications (1)

Publication Number Publication Date
KR950703962A true KR950703962A (ko) 1995-11-17

Family

ID=6474850

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019950702355A KR950703962A (ko) 1992-12-10 1993-12-06 중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System)

Country Status (13)

Country Link
US (1) US5612344A (ko)
EP (1) EP0673249B1 (ko)
JP (1) JPH08504418A (ko)
KR (1) KR950703962A (ko)
AT (1) ATE177637T1 (ko)
AU (1) AU673225B2 (ko)
CA (1) CA2151241A1 (ko)
CZ (1) CZ144895A3 (ko)
DE (2) DE4241564A1 (ko)
MX (1) MX9307837A (ko)
NZ (1) NZ258887A (ko)
WO (1) WO1994013294A1 (ko)
ZA (1) ZA939229B (ko)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH490362A (de) * 1967-04-03 1970-05-15 Upjohn Co Verfahren zur Herstellung von 20-Ketosteroidverbindungen
DE3146599A1 (de) * 1981-11-25 1983-07-07 Basf Ag, 6700 Ludwigshafen Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen
US4713383A (en) * 1984-10-01 1987-12-15 Ciba-Geigy Corporation Triazoloquinazoline compounds, and their methods of preparation, pharmaceutical compositions, and uses
EP0181282A1 (de) * 1984-10-01 1986-05-14 Ciba-Geigy Ag Triazolochinazolinverbindungen
US5153196A (en) * 1991-06-05 1992-10-06 Eli Lilly And Company Excitatory amino acid receptor antagonists and methods for the use thereof

Also Published As

Publication number Publication date
CZ144895A3 (en) 1995-12-13
MX9307837A (es) 1994-07-29
JPH08504418A (ja) 1996-05-14
ZA939229B (en) 1995-06-09
EP0673249A1 (de) 1995-09-27
ATE177637T1 (de) 1999-04-15
AU5696594A (en) 1994-07-04
CA2151241A1 (en) 1994-06-23
DE4241564A1 (de) 1994-06-16
AU673225B2 (en) 1996-10-31
WO1994013294A1 (de) 1994-06-23
DE59309469D1 (de) 1999-04-22
US5612344A (en) 1997-03-18
EP0673249B1 (de) 1999-03-17
NZ258887A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
ITMI922006A1 (it) Esteri nitrici di derivati dell'acido 2-(2, 6-di-alo-fenilammino) fenilacetico e procedimento per la loro preparazione
RU98108027A (ru) Производные имидазола, обладающие аффинностью в отношении активности альфа2- рецепторов
OA09482A (fr) "Nouveaux dérivés à structure naphtalénique, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent".
BR9510452A (pt) Composição farmacêutica e aquosa estéril para a administração parenteral processos para limitar o potencial de crescimento microbiano em composição farmacêutica estéril para a administração parenteral para produzir anestesia em um animal de sangue quente e para aperfeiçoar o tempo de administração e/ou o tempo entre as trocas de conjuntos
MX9710261A (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
KR950704283A (ko) 신경제제로서 유용한 1,4-벤조티아제핀(1,4-Benzothiazepines useful as neurological agents)
IS4218A (is) Hliðstæð aðferð við að framleiða skammvirk tvíhýdrópýridín
RU99127433A (ru) Эрголиновые производные и их применение в качестве антагонистов рецепторов соматостатина
SE9601677D0 (sv) New use
BR9507231A (pt) Uso de derivados de ácido carboxílico para a produção de drogas
KR880013886A (ko) 신규 알칸술폰아닐리드 유도체, 그의 제조방법 및 이를 함유하는 제약 조성물
ATE150745T1 (de) 22-en-25-oxa-derivate in der vitamin d-reihe, verfahren zu ihrer herstellung, diese derivate enthaltenen pharmazeutische präparate sowie deren verwendung als arzneimittel
FI964482A (fi) Amidijohdannaisia ja niiden käyttö lääkkeenä
LV11323A (lv) Izohinolina atvasinajumi ka arstnieciskie lidzekli
KR950703962A (ko) 중추 신경계 질병을 치료하기 위한 트리아 졸로퀴나졸린(Triazoloquinazolines for the Treatment of Diseases of the Central Nervous System)
RU94046144A (ru) Замещенные (арилалкиламинобензил) аминопропионамидные производные, их применение, способы их получения, фармкомпозиция
KR950018047A (ko) 18 환 원자를 갖는 신규한 사이클릭 뎁시펩타이드 및 내부 기생충을 구제하는 이의 용도
KR890006621A (ko) 항불안제
KR880007498A (ko) 중추작용 근이완제
RU2002132883A (ru) Новые полициклические инданилимидазолы, обладающие альфа2 адренергической активностью
KR930703013A (ko) 항당뇨병제로서 유용한 신규한 글루코하이드롤라제 억제제
KR960705791A (ko) 기억력 향상제로서 유용한 3-아릴-4-알킬 및 4,5-디알킬-4H-1,2,4-트리아졸(3Aryl-4-alkyl and 4,5-dialkyl-4H-1,2,4-triazoles useful as memory enhancers)
ES2109512T3 (es) Macrolactama (ciclamenol) antiinflamatoria.
KR930019640A (ko) 테트라히드로피리미딘 유도체
DE59309898D1 (de) 4-oxo-azetidin-2-sulfonsäureamide und ihre salze, verfahren zu deren herstellung und ihre verwendung

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid